---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000182739.md"
description: "$Eli Lilly(LLY.US) (-8% pre-mkt, long position) as disappointing data on its new weight loss pill overshadowed a solid 2Q sales beat and good 3Q guidance from its current injectable obesity drugs.  In Phase 3 trials, the new pill's results showed lower weight loss and higher rates of nausea and vomiting, side effects associated with GLP-1 drugs. Lilly's data raise doubts over whether the once daily pill, called orforglipron and which is expected for 2026 release can meet Wall Street's estimates of $12B in annual sales by 2030.Once a day pills are a key part of reaching more patients in the market that’s expected to grow to $95 billion by 2030.  In Lilly’s pill study, patients on the highest dose shed roughly 11% of their body weight, or 25 pounds, the company said. In late-stage trials, patients on an oral version  of Novo’s Wegovy lost about 16% of their weight over a 68-week period.   About 10% of patients dropped out of the study due to side effects such as nausea and vomiting. Orforglipron is easier to manufacture than its current injectable Zepbound and is expected to be a cheaper option for patients.3Q guidance:- Rev $60.0B - $62.0B, saw $58.0B to $61.0b, vs 60.1B est. - Adj EPS $21.75 to $23.00, saw $20.78 to $22.282Q results:- Adj EPS $6.31 vs. $5.57 expected- Rev $15.56B, +38% y/y, vs $14.7B est.- Zepbound Rev $3.38B vs $3.07B est- Mounjaro Rev $5.20B vs $4.50B est.- Trulicity Rev $$1.09B vs $1.04B estConf call 830ET"
datetime: "2025-08-07T12:57:57.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000182739.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000182739.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000182739.md)
author: "[Gary Black Tracker](https://longbridge.com/en/profiles/17077344.md)"
generator: "portal-rs"
---

# $Eli Lilly(LLY.US) (-8% pre-mkt, long position) as…


### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**